Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

macitentan

- PMLiVE

J&J files rare blood disorder drug siltuximab in US and EU

Orphan drug to be assessed for use in the treatment of multicentric Castleman disease

Bayer symbol

Bayer moves closer to US approval of PAH drug riociguat

FDA panel votes unanimously in favour of hypertension treatment

- PMLiVE

J&J files ‘breakthrough’ drug ibrutinib in US

FDA to assess drug in lymphoma and leukaemia

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

J&J expects to file 10 new pharma products by 2017

Healthcare company also expects 25 significant brand-line extensions

- PMLiVE

J&J’s Simponi wins FDA approval in ulcerative colitis

Adds to rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis indications in the US

- PMLiVE

FDA says Janssen’s myeloma drug is a ‘breakthrough therapy’

Should speed up regulatory process for daratumumab

Bayer symbol

Bayer’s riociguat fast-tracked by FDA

Could provide oral option in pulmonary arterial hypertension market

- PMLiVE

Janssen’s first-in-class diabetes drug Invokana wins US approval

Will be first SGLT2 inhibitor to reach the market in the States

- PMLiVE

Bayer submits oral PAH drug riociguat for approval

Set to challenge Actelion and Gilead

- PMLiVE

Interview: Cesar Rodriguez, Janssen

Managing director of Janssen UK & Ireland, Cesar Rodriguez is relishing being in the UK market, after years working across Europe and North Africa

EU flag

Five pharma companies begin antibiotic research programme

Sanofi, GSK and AstraZeneca among the collaborators on European projects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links